Drug reference
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or insulin ▶BY MOUTH ▶Adult: 1 tablet twice daily, based on patient’s current metformin dose
PDF page 755
Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (June 2013) that Komboglyze ® is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus in patients unable to achieve adequate glycaemic control with metformin alone and when the addition of a sulfonylurea is inappropriate.
PDF page 755
→Appendix 1: metformin. saxagliptin
PDF page 755
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Komboglyze (AstraZeneca UK Ltd) Saxagliptin (as Saxagliptin hydrochloride) 2.5 mg, Metformin hydrochloride 850 mg Komboglyze 2.5mg/850mg tablets | 56 tablet P £31.60 DT = £31.60 Saxagliptin (as Saxagliptin hydrochloride) 2.5 mg, Metformin hydrochloride 1 gram Komboglyze 2.5mg/1000mg tablets | 56 tablet P £31.60 DT = £31.60
PDF page 755
1 tablet twice daily, based on patient’s current
First-line fragment. Read the complete Indications and Dose section above.
PDF page 755
